108 Open Dispensaries Made Non-Compliant Overnight.

OCM's decision to reverse Guidance Memo 2022-04 retroactively — rather than grandfathering existing businesses and applying the new methodology only to future applications — is the central governance failure. Administrative agencies have broad authority to correct guidance errors, but due process protections typically require prospective application.

The Governor's signature on S.8742-B in February 2026 was the ultimate resolution. The fact that a legislative fix was required — rather than an administrative correction by OCM — reflects the severity of the agency's error and the political importance of the 108 affected businesses. The legislative fix was also a public rebuke of OCM's process.

The twelve operators who filed suit provided the political pressure that accelerated the legislative fix. Their due process argument — that retroactive application of a new measurement methodology violated reasonable reliance on agency guidance — was legally sound and politically compelling. The legislative fix mooted the litigation.

The 108 affected businesses represented a politically significant constituency — they included CAURD (Conditional Adult-Use Retail Dispensary) licensees, many of them justice-involved individuals who were specifically prioritized by New York's equity-focused cannabis licensing framework. Their political vulnerability accelerated the legislative response.

The Legislature's passage of S.8742-B reflects a legislature uncomfortable with OCM's retroactive guidance reversal. The bill's bipartisan passage sent a signal to the agency about the limits of retroactive regulatory correction. The legislative fix was the correct substantive outcome — but the process failure remains documented.

Cannabis attorneys in New York began advising clients to monitor OCM advisory publications as a critical compliance obligation after this episode. Regulatory interpretation risk — the possibility that an agency changes how it applies existing rules — is now recognized as a distinct risk category in New York cannabis site analysis.